Forging the Future of Healthcare in the Netherlands
The Netherlands is clearly a fertile environment for its 2,200 life science and medtech companies. However, the Dutch ambition to be a frontrunner in new healthcare challenges also comprises an…
Address: Wilgenlaan 5 • 1161 JK Zwanenburg,Netherlands
Tel: 31 (0) 20 / 407 20 72
Web: http://www.daiichi-sankyo.nl/
DAIICHI SANKYO’s goal is to establish itself as a ‘Global Pharma Innovator.’ The pharmaceutical industry is one of the 21st century’s growth industries, and what this vision of the company signifies is DAIICHI SANKYO making it the leading industry of Japan, a nation built on the platform of scientific and technological creativity, and establishing itself as a firm presence by continued success as a flagship company. This is the vision that guides the development of our global pharmaceutical operations.
DAIICHI SANKYO’s products are used not only in Japan but also in many parts of the world including Asia, Europe and the United States. To pick up on global needs all over the world and have these reflected in global pharmaceutical operations, we are active in promoting information exchange in a number of areas including research and development, supply chain management and marketing.
We are determined to contribute to the health of people everywhere by creating new medicines in popular use throughout the world, and delivering them to places where medical treatment is required, transcending national borders.
We have about 2,300 overseas medical representatives in 33 locations, mainly in Europe and the United States. From this point on, we are aiming for growth through our own development and sales, mainly in the United States, and to this end, we are planning to expand our overseas development and sales bases. While making efforts to develop innovative new medicines, we have become established as a firm presence in the global market for pharmaceutical products by implementing the highest standard of operational efficiency in the industry in order to ‘respond to the medical needs of people everywhere.’
Our U.S. subsidiary, Daiichi Sankyo, Inc. (DSI) has research and development and sales sections, and as the organization that forms the nucleus of our U.S. operations, is expected to grow in the future.
Our European subsidiary, Daiichi Sankyo Europe GmbH (DSE), is headquartered in Munich, Germany, and has around 800 medical representatives in operational bases in 10 European countries.
The Netherlands is clearly a fertile environment for its 2,200 life science and medtech companies. However, the Dutch ambition to be a frontrunner in new healthcare challenges also comprises an…
Sobi is a leading integrated biopharmaceutical company dedicated to developing innovative therapies and services to improve the lives of rare disease patients and their families. Karel Fol, the country manager…
Paul Korte, General Manager for Janssen in the Netherlands, highlights the strategic move and leadership position taken up by Janssen in the oncology field, and calls on Dutch healthcare stakeholders…
In an exclusive interview, the Vice President of Philips Research explains the key to continuous evolution, improving healthcare stakeholder relations, and fostering “Open Innovation.” You have been Vice President of…
Healthcare is moving towards an increased level of personalization and active participation of the patient in the decision-making process. Roland van Esch, General Manager of Zimmer Biomet Netherlands, shares his…
Teva Benelux and Nordics’ GM lifts the lid on how the company has grown to become the market leader in the Netherlands. Looking at Teva’s activities, your market leader position in…
Takeda’s goal is to become a trusted and reliable partner in the healthcare system by better understanding patients’ needs. Aarnoud Overkamp, general manager of the Dutch subsidiary, shares his perspective…
In many aspects, 2016 truly marks the dawn of a new era for Toshiba Medical Systems. Lo Wuite (LW), General Manager Managed Equipment Services (MES) Europe, and Dick Blesing (DB),…
DHL Supply Chain Benelux understands the challenges life sciences companies face and has developed solutions to help overcome them. The Vice President and Commercial Director discuss how the services of…
Yvonne van Rooy, president of the NVZ, explains the patient’s increasing role as a partner in Dutch healthcare and how greater investment in ICT is needed for the patient to fulfill this role. She further discusses…
After having successfully acquired its first dialysis center in the Netherlands, Fresenius Medical Care, the market leader for kidney failure products and services, is looking to develop more partnerships with…
Ad Schuurman of the National Health Care Institute of the Netherlands (“Zorginstituut”) explains the main missions and mandates of this organization with regards to the basic insurance package covering all Dutch citizens,…
See our Cookie Privacy Policy Here
